Clinical Trials
90 trialsModified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.
the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
RenJi Hospital
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
MIKE-1
Nagoya University
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Fudan University
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Tongji Hospital
Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
Xijing Hospital
FUTURE-SUPER
Fudan University
SPARK
Fudan University
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients
Fudan University
BRPCNCC-1
Changhai Hospital
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
MARIO-3
Infinity Pharmaceuticals, Inc.
ERI-Based-01
Fujian Cancer Hospital
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
Shanghai Zhongshan Hospital
Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer
Hunan Cancer Hospital
Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
NeoPATH
Ruijin Hospital
FOOTPATH
Ludwig-Maximilians - University of Munich
FUTURE
Fudan University
HIFU
The First Affiliated Hospital with Nanjing Medical University
Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis:Single-arm, Prospective Clinical Study
Zhongshan Hospital Xiamen University
Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer
Xijing Hospital
NURE-Combo
IRCCS San Raffaele
imPaCT-PRO
Institute of Molecular Medicine and Biomedical Research
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
ChineseAMS
INSIGHT
Fudan University
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Fudan University
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
Ruijin Hospital
SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Jiangsu HengRui Medicine Co., Ltd.
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer
Shengjing Hospital
Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
The First Hospital of Jilin University
Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
Tianjin Medical University Cancer Institute and Hospital
Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Pyramid
Tianjin Medical University Cancer Institute and Hospital
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Sun Yat-sen University
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer
Huazhong University of Science and Technology
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer
Peking Union Medical College Hospital
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
Tianjin Medical University Cancer Institute and Hospital
Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
Tang-Du Hospital
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Fudan University
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer
The First Affiliated Hospital of Xiamen University